Article Sidebar
Published:
May 28, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
C1q/tumor necrosis factor (TNF)-associated protein 6 (CTRP6) ameliorates the cognitive dysfunction induced by sevoflurane by activating AMPK/SIRT1 pathway in rats
Abstract
Purpose: To evaluate the possible effects of C1q/tumor necrosis factor (TNF)-associated protein 6 (CTRP6) on postoperative cognitive dysfunction (POCD), including the potentially-related signaling pathway.
Methods: Behavioral analysis and cognitive impairment were assessed in each group. Immunoblots were used to determine the level of CTRP6 following sevoflurane-induced nerve injury. Hippocampal neurons were identified using Nissl staining, while inflammatory response following neuronal injury was monitored by enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction (qPCR). The involvement of adenosine monophosphate-activated protein kinase (AMPK)/sirtuin 1 (SIRT1) pathway was determined using immunoblot.
Results: CTRP6 alleviated sevoflurane-induced cognitive dysfunction in rats (p < 0.001). Moreover, CTRP6 reduced sevoflurane-induced nerve injury and inflammation in rats (p < 0.05).
Conclusion: CTRP6 ameliorates sevoflurane-induced cognitive dysfunction by activating AMPK/SIRT1 pathway, thus offering a novel target for POCD treatment.
